---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-26-000023"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2026-08-05T20:02:17+00:00"
generated_at: "2026-08-05T20:03:12.530080+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics Q2 2026 net loss $9.9M; silevertinib shows 60% ORR in NSCLC

## Summary
- Cash, equivalents, and investments $110.5M as of June 30, 2026; runway into 2H 2028.
- Net loss $9.9M vs $10.6M in Q2 2025; R&D expenses $7.4M, G&A $4.7M.
- Phase 2 silevertinib in frontline non-classical EGFRm NSCLC: ORR 60%, CNS ORR 86%, median PFS 15.2 months.
- No patients developed de novo brain metastases; 53% remain on therapy, longest 23.5 months.
- FDA feedback on pivotal path for silevertinib in frontline NSCLC expected Q4 2026.

## SEC filing metadata
- accession: 0001701541-26-000023
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2026-08-05T20:02:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/0001701541-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154126000023/bdtx-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-26-000023
- JSON: https://secwatch.observer/filing/0001701541-26-000023.json
- Plain text: https://secwatch.observer/filing/0001701541-26-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.